Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $22.6 million, representing a 53% increase compared to the prior year period [6][18] - Gross margin reached 50.6%, up 11 points year over year, marking the first time it surpassed 50% [7][19] - The company expects continued gross margin expansion, aiming for over 70% in the coming years [8][19] Business Line Data and Key Metrics Changes - Approximately 4,700 prescriptions were written for the Assure system in Q2 2026, contributing to revenue growth [6] - Revenue growth was driven by a 54% year-over-year increase in prescriptions, reflecting market share gains and activation of new accounts [18] Market Data and Key Metrics Changes - The wearable cardioverter defibrillator (WCD) market is underutilized, with only 14% of the eligible U.S. addressable market currently receiving therapy [9] - The WCD market growth has accelerated to low double digits, indicating a multi-billion-dollar market potential in the coming years [13] Company Strategy and Development Direction - The company is focused on expanding its sales organization to penetrate existing accounts and attract new prescribers [13][14] - The strategy includes enhancing revenue cycle management capabilities and increasing the in-network patient mix, which has improved from approximately 70% to the low 80s [15][19] - The company is investing in clinical evidence generation to influence clinical practice and guidelines [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong growth, supported by a robust clinical evidence base and an expanding market [17][21] - The company is increasing its fiscal year 2026 revenue guidance to $91 million, reflecting a growth of 52% compared to fiscal year 2025 [21][22] Other Important Information - GAAP operating expenses were $43.2 million in Q2, including non-recurring costs related to professional fees and the recent equity offering [20] - The company reported a GAAP net loss of $32.8 million for the quarter, compared to a loss of $20.6 million in the prior year [21] Q&A Session Summary Question: Guidance for the year and Q3 seasonality - Management discussed the importance of tracking performance on a daily, weekly, and monthly basis, emphasizing a focus on prescription volume growth and in-network mix [25] Question: Use of proceeds from the recent equity offering - The company plans to use the additional capital to strengthen its balance sheet and support key growth drivers [27] Question: Impact of AHA data on market growth - Management noted that the WCD market growth is low double digits, with anecdotal evidence suggesting an increase in clinician awareness and interest following the presentation of clinical data [29] Question: Path for guideline updates - Management clarified that while growth does not rely on guideline changes, they believe the clinical evidence warrants a review [33] Question: Prescription volume sustainability - Management expressed confidence in sustaining prescription growth above 50%, driven by ongoing penetration of existing accounts and the addition of new hospitals [41]